{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:22:32Z","timestamp":1768314152218,"version":"3.49.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T00:00:00Z","timestamp":1438732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ctrv.2015.07.005","type":"journal-article","created":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T06:54:09Z","timestamp":1438412049000},"page":"827-835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Clinical characteristics of patients with relapsed multiple myeloma"],"prefix":"10.1016","volume":"41","author":[{"given":"Meletios A.","family":"Dimopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2015.07.005_b0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2015.07.005_b0010","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2015.07.005_b0015","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2015.07.005_b0020","unstructured":"National Comprehensive Care Network. Clinical practice guidelines in oncology. Multiple myeloma. Available from: <http:\/\/www.nccn.org>; 2015 [accessed February 2015]."},{"key":"10.1016\/j.ctrv.2015.07.005_b0025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.leu.2405016","article-title":"Clinically relevant end points and new drug approvals for myeloma","volume":"22","author":"Anderson","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2015.07.005_b0030","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2141.2012.09232.x","article-title":"An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and\/or refractory multiple myeloma who have been previously treated with bortezomib","volume":"158","author":"Vij","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0035","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/asheducation-2010.1.303","article-title":"Relapsed multiple myeloma","author":"Lonial","year":"2010","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ctrv.2015.07.005_b0040","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1634\/theoncologist.2014-0042","article-title":"European perspective on multiple myeloma treatment strategies in 2014","volume":"19","author":"Ludwig","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2015.07.005_b0045","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"International Myeloma Workshop Consensus. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.07.005_b0050","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2007-03-081018","article-title":"Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group","volume":"111","author":"Ludwig","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.07.005_b0055","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.07.005_b0060","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejca.2009.07.006","article-title":"Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989","volume":"46","author":"Schaapveld","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2015.07.005_b0065","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.blre.2013.04.001","article-title":"Management of older adults with multiple myeloma","volume":"27","author":"Palumbo","year":"2013","journal-title":"Blood Rev"},{"key":"10.1016\/j.ctrv.2015.07.005_b0070","unstructured":"National Cancer Institute. SEER (Surveillance, Epidemiology and End Results) Cancer Statistics Review, 1975\u20132010. Available from: <http:\/\/seer.cancer.gov\/archive\/csr\/1975_2004\/results_merged\/sect_18_myeloma.pdf> [accessed February 2015]."},{"key":"10.1016\/j.ctrv.2015.07.005_b0075","first-page":"765","article-title":"A second autologous stem cell transplant (ASCT2) induces superior durability of response (DuR) following bortezomib-containing re-induction therapy for relapsed multiple myeloma (MM): final results from the BSBMT\/UKMF Myeloma X (Intensive) trial","volume":"122","author":"Cook","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2015.07.005_b0080","first-page":"1964","article-title":"A new multinational observational study in multiple myeloma: initial report of the PREAMBLE Study","volume":"122","author":"Vij","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2015.07.005_b0085","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ctrv.2015.07.005_b0090","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","volume":"30","author":"Garderet","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0095","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2015.07.005_b0100","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0105","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","article-title":"An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma","volume":"119","author":"Vij","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.07.005_b0110","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/1078-0432.CCR-12-3352","article-title":"Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma","volume":"19","author":"Niesvizky","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.07.005_b0115","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2013-07-511170","article-title":"Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma","volume":"122","author":"Wang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.07.005_b0120","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0125","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1182\/blood-2013-07-517276","article-title":"A phase 2 trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed\/refractory myeloma","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.07.005_b0130","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3324\/haematol.2013.084376","article-title":"Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma","volume":"98","author":"Dimopoulos","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2015.07.005_b0135","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0140","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2015.07.005_b0145","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2015.07.005_b0150","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","article-title":"Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study","volume":"14","author":"Dimopoulos","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0155","first-page":"302","article-title":"Final results for the 1703 phase 1b\/2 study of elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"124","author":"Richardson","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2015.07.005_b0160","first-page":"4766","article-title":"Velcade, thalidomide, dexamethasone and panobinostat (VTD-P) for patients with relapsed and relapsed\/refractory myeloma: preliminary results of the Muk-Six phase I\/IIa trial","volume":"124","author":"Popat","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2015.07.005_b0165","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0170","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2015.07.005_b0175","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.07.005_b0180","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1200\/JCO.1989.7.12.1839","article-title":"Prognostic factors in multiple myeloma: definition of risk groups in 410 previously untreated patients: a Grupo Argentino de Tratamiento de la Leucemia Aguda study","volume":"7","author":"Corrado","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0185","first-page":"4733","article-title":"Combined treatment of bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study","volume":"124","author":"Waal","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2015.07.005_b0190","first-page":"3470","article-title":"Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: final results of a national multicenter randomized controlled phase III study","volume":"124","author":"Kropff","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2015.07.005_b0195","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.07.005_b0200","first-page":"687","article-title":"A simple score, based on geriatric assessment, improves prediction of survival, and risk of serious adverse events in elderly newly diagnosed multiple myeloma patients","volume":"122","author":"Lacrocca","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2015.07.005_b0205","unstructured":"Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma: an International Myeloma Working Group report. Blood. Epub 2015 Jan 27. pii: blood-2014-12-615187."},{"key":"10.1016\/j.ctrv.2015.07.005_b0210","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4137\/CMO.S8014","article-title":"Current and emerging treatment options for patients with relapsed myeloma","volume":"7","author":"Castelli","year":"2013","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0215","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1182\/asheducation-2009.1.566","article-title":"How to treat elderly patients with multiple myeloma: combination of therapy or sequencing","author":"Palumbo","year":"2009","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ctrv.2015.07.005_b0220","first-page":"4779","article-title":"Multicenter phase II trial of bendamustine, lenalidomide and dexamethasone (BRd) as 2nd-line therapy for multiple myeloma","volume":"124","author":"Mey","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2015.07.005_b0225","first-page":"4735","article-title":"Phase I\/II trial of weekly escalated dose bortezomib combined with lenalidomide and dexamethasone in patients in first relapse or primary refractory disease after first line therapy for multiple myeloma","volume":"124","author":"Broijl","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2015.07.005_b0230","unstructured":"European Medicines Agency. European Medicines Agency Scientific Discussion. Available from: <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000717\/WC500056022.pdf>. [accessed February 2015]."},{"key":"10.1016\/j.ctrv.2015.07.005_b0235","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/leu.2009.134","article-title":"Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis","volume":"23","author":"Landgren","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2015.07.005_b0240","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/ajh.22025","article-title":"Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients","volume":"86","author":"Weiss","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0245","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.07.005_b0250","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2012.46.3323","article-title":"Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States","volume":"31","author":"Warren","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0255","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1002\/cncr.25297","article-title":"Access to hematopoietic stem cell transplantation: effect of race and sex","volume":"116","author":"Joshua","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2015.07.005_b0260","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.07.005_b0265","first-page":"3399","article-title":"Cohort analysis of FISH testing of CD138+ cells in relapsed multiple myeloma: implications for prognosis and choice of therapy","volume":"124","author":"Smith","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2015.07.005_b0270","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1038\/bcj.2013.58","article-title":"Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study","volume":"3","author":"Offidani","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ctrv.2015.07.005_b0275","first-page":"4734","article-title":"Bendamustine, bortezomib and dexamethasone (BVD) in patients with relapsed-refractory multiple myeloma (MM): updated results of a multicenter phase II study","volume":"124","author":"Offidani","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2015.07.005_b0280","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2015.07.005_b0285","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood.V63.2.468.468","article-title":"Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment \u2013 a prospective study of 160 patients","volume":"63","author":"Bataille","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.07.005_b0290","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood.V75.4.823.823","article-title":"Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study","volume":"75","author":"Durie","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.07.005_b0295","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1365-2141.1990.tb07790.x","article-title":"Long-term prognostic value of serum beta 2 microglobulin in myelomatosis","volume":"75","author":"Cuzick","year":"1990","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0300","first-page":"8018","article-title":"Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed\/refractory multiple myeloma","volume":"30","author":"Orlowski","year":"2012","journal-title":"J Clin Oncol (ASCO Annual Meeting Proceedings)"},{"key":"10.1016\/j.ctrv.2015.07.005_b0305","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/leu.2011.204","article-title":"A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial","volume":"26","author":"Boyd","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2015.07.005_b0310","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/leu.2012.282","article-title":"Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project","volume":"27","author":"Avet-Loiseau","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2015.07.005_b0315","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3324\/haematol.2009.016436","article-title":"Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation","volume":"95","author":"Neben","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2015.07.005_b0320","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3109\/10428194.2012.746683","article-title":"Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse","volume":"54","author":"Papanikolaou","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"Suppl. 7","key":"10.1016\/j.ctrv.2015.07.005_b0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12325-011-0079-0","article-title":"Multiple myeloma with extramedullary disease","volume":"28","author":"Oriol","year":"2011","journal-title":"Adv Ther"},{"key":"10.1016\/j.ctrv.2015.07.005_b0330","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.leukres.2013.11.010","article-title":"Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma","volume":"38","author":"Zhuang","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2015.07.005_b0335","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/1471-2407-14-462","article-title":"Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival","volume":"14","author":"Kiba","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2015.07.005_b0340","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.clml.2011.07.001","article-title":"Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma","volume":"11","author":"Gkotzamanidou","year":"2011","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"10.1016\/j.ctrv.2015.07.005_b0345","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1182\/blood-2014-11-612069","article-title":"Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and\/or translocation (4;14): IFM 2010\u201302","volume":"125","author":"Leleu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.07.005_b0350","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/sj.leu.2404442","article-title":"Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials","volume":"21","author":"Jagannath","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2015.07.005_b0355","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2012-05-432203","article-title":"Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma","volume":"121","author":"Bergsagel","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.07.005_b0360","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1600-0609.2008.01131.x","article-title":"Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE","volume":"81","author":"Srikanth","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0365","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1034\/j.1600-0609.2000.90221.x","article-title":"Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group","volume":"65","author":"Knudsen","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0370","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1600-0609.2009.01318.x","article-title":"Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients","volume":"83","author":"Kleber","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0375","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 \u2013 Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0380","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2009-06-225854","article-title":"Sensitivity of serum free light chain measurement of residual disease in multiple myeloma patients","volume":"114","author":"Mead","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.07.005_b0385","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2141.2005.05366.x","article-title":"Toxicity in standard melphalan\u2013prednisone therapy among myeloma patients with renal failure \u2013 a retrospective analysis and recommendations for dose adjustment","volume":"128","author":"Carlson","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0390","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0395","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1002\/cncr.25139","article-title":"The efficacy and safety of lenalidomide plus dexamethasone in relapsed and\/or refractory multiple myeloma patients with impaired renal function","volume":"116","author":"Dimopoulos","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2015.07.005_b0400","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2141.2007.06698.x","article-title":"Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-na\u00efve patients undergoing front-line lenalidomide and dexamethasone therapy","volume":"138","author":"Niesvizky","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0405","unstructured":"Celgene-Revlimid. REVLIMID Prescribing Information. Available from: <http:\/\/www.revlimid.com\/wp-content\/uploads\/2013\/11\/PI.pdf> [accessed February 2015]."},{"key":"10.1016\/j.ctrv.2015.07.005_b0410","first-page":"8542","article-title":"The efficacy and safety of lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma patients with impaired renal function","volume":"26","author":"Weber","year":"2008","journal-title":"J Clin Oncol (ASCO Annual Meeting Proceedings)"},{"key":"10.1016\/j.ctrv.2015.07.005_b0415","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/sj.leu.2405087","article-title":"Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study","volume":"22","author":"San-Miguel","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2015.07.005_b0420","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/leu.2013.29","article-title":"Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety","volume":"27","author":"Badros","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2015.07.005_b0425","unstructured":"VELCADE\u00ae (bortezomib) Prescribing Information. Cambridge, MA; Millenium Pharmaceuticals, Inc. Available from: <http:\/\/www.velcade.com\/Files\/PDFs\/VELCADE_PRESCRIBING_INFORMATION.pdf>; 2014."},{"key":"10.1016\/j.ctrv.2015.07.005_b0430","first-page":"4755","article-title":"Pomalidomide+low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma and renal impairment: analysis of patients from the phase 3b stratus trial (MM-010)","volume":"124","author":"Weisel","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2015.07.005_b0435","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3324\/haematol.2009.012674","article-title":"Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations","volume":"95","author":"Mohty","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2015.07.005_b0440","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2015.07.005_b0445","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0450","first-page":"1297","article-title":"An ongoing multinational observational study in multiple myeloma (PREAMBLE): initial assessment of treatment patterns in patients with \u2a7e6months follow-up","volume":"124","author":"Vij","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"Suppl. 13","key":"10.1016\/j.ctrv.2015.07.005_b0455","first-page":"1","article-title":"Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma","volume":"4","author":"Richardson","year":"2006","journal-title":"Clin Adv Haematol Oncol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0460","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12185-013-1294-z","article-title":"Current approaches for the treatment of multiple myeloma","volume":"97","author":"Watanabe","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ctrv.2015.07.005_b0465","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3816\/CLM.2008.n.016","article-title":"An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma","volume":"8","author":"Conner","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.ctrv.2015.07.005_b0470","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1182\/blood-2011-04-350009","article-title":"Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma","volume":"118","author":"Madan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.07.005_b0475","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1634\/theoncologist.2009-0203","article-title":"Current multiple myeloma treatment strategies with novel agents: a European perspective","volume":"15","author":"Ludwig","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2015.07.005_b0480","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/jcpt.12020","article-title":"Real-world health care costs of relapsed\/refractory multiple myeloma during the era of novel cancer agents","volume":"38","author":"Gaultney","year":"2013","journal-title":"J Clin Pharm Ther"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737215001504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737215001504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T19:31:06Z","timestamp":1599420666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737215001504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":96,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0305737215001504"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.07.005","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics of patients with relapsed multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}